These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 34638258)
21. Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives. Crocetto F; Russo G; Di Zazzo E; Pisapia P; Mirto BF; Palmieri A; Pepe F; Bellevicine C; Russo A; La Civita E; Terracciano D; Malapelle U; Troncone G; Barone B Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805043 [TBL] [Abstract][Full Text] [Related]
22. Precision medicine for advanced prostate cancer. Mullane SA; Van Allen EM Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474 [TBL] [Abstract][Full Text] [Related]
23. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods]. Pfarr N; Merkelbach-Bruse S Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463 [TBL] [Abstract][Full Text] [Related]
24. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276 [TBL] [Abstract][Full Text] [Related]
25. Liquid biopsy: current technology and clinical applications. Nikanjam M; Kato S; Kurzrock R J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847 [TBL] [Abstract][Full Text] [Related]
27. The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. Khaddour K; Felipe Fernandez M; Khabibov M; Garifullin A; Dressler D; Topchu I; Patel JD; Weinberg F; Boumber Y Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358724 [TBL] [Abstract][Full Text] [Related]
28. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine? Miyamoto DT; Lee RJ Urol Oncol; 2016 Nov; 34(11):490-501. PubMed ID: 27771279 [TBL] [Abstract][Full Text] [Related]
29. Homologous Recombination Repair Deficiency: An Overview for Pathologists. Doig KD; Fellowes AP; Fox SB Mod Pathol; 2023 Mar; 36(3):100049. PubMed ID: 36788098 [TBL] [Abstract][Full Text] [Related]
30. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476 [TBL] [Abstract][Full Text] [Related]
31. Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Tan CR; Zhou L; El-Deiry WS Curr Colorectal Cancer Rep; 2016 Jun; 12(3):151-161. PubMed ID: 27516729 [TBL] [Abstract][Full Text] [Related]
32. ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration. Cui X; Yu H; Yao J; Li J; Li Z; Jiang Z BMC Cancer; 2022 Dec; 22(1):1350. PubMed ID: 36564767 [TBL] [Abstract][Full Text] [Related]
33. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892 [TBL] [Abstract][Full Text] [Related]